VIA

Vaccination In Atherosclerosis

 Coordinatore UNIVERSITEIT LEIDEN 

 Organization address address: RAPENBURG 70
city: LEIDEN
postcode: 2300 RA

contact info
Titolo: Mr.
Nome: Ton
Cognome: Brouwer
Email: send email
Telefono: +31 71 5273149
Fax: +31 71 5275269

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 8˙136˙785 €
 EC contributo 5˙994˙233 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-12-01   -   2018-11-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN

 Organization address address: RAPENBURG 70
city: LEIDEN
postcode: 2300 RA

contact info
Titolo: Mr.
Nome: Ton
Cognome: Brouwer
Email: send email
Telefono: +31 71 5273149
Fax: +31 71 5275269

NL (LEIDEN) coordinator 1˙158˙815.50
2    STICHTING CENTRE FOR HUMAN DRUG RESEARCH

 Organization address address: ZERNIKEDREEF 10
city: LEIDEN
postcode: 2333 CL

contact info
Titolo: Prof.
Nome: Koos
Cognome: Burggraaf
Email: send email
Telefono: +31 715246400
Fax: +31 715246499

NL (LEIDEN) participant 731˙000.20
3    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Dr.
Nome: Jacqueline
Cognome: Postma
Email: send email
Telefono: +46 40 39 12 36
Fax: +46 40 39 12 22

SE (LUND) participant 640˙000.00
4    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Mrs.
Nome: Caroline
Cognome: Hamilton
Email: send email
Telefono: 46851775959

SE (STOCKHOLM) participant 565˙001.00
5    CARDIOVAX LLC

 Organization address address: GLENBARR AVENUE 10345
city: LOS ANGELES CA
postcode: 90064

contact info
Titolo: Dr.
Nome: Mark
Cognome: Carvlin
Email: send email
Telefono: +1 6095145300
Fax: +1 6095145301

US (LOS ANGELES CA) participant 527˙500.00
6    GOETEBORGS UNIVERSITET

 Organization address address: VASAPARKEN
city: GOETEBORG
postcode: 405 30

contact info
Titolo: Dr.
Nome: Ellen
Cognome: Rydberg
Email: send email
Telefono: +46 31 786 6470
Fax: +46 31 786 4355

SE (GOETEBORG) participant 452˙550.00
7    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Ms.
Nome: Renata
Cognome: Schaeffer
Email: send email
Telefono: +441223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) participant 452˙500.00
8    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Dr.
Nome: Giuseppina
Cognome: Caligiuri
Email: send email
Telefono: +33 140257556
Fax: +33 140258602

FR (PARIS) participant 452˙254.00
9    MEDIZINISCHE UNIVERSITAET WIEN

 Organization address address: SPITALGASSE 23
city: WIEN
postcode: 1090

contact info
Titolo: Prof.
Nome: Christoph
Cognome: Binder
Email: send email
Telefono: +43 1 40400 73755
Fax: +43 1 40400 73588

AT (WIEN) participant 451˙972.00
10    BRENNTAG NORDIC AS/BRENNTAG BIOSECTOR AS

 Organization address address: STRANDVEJEN 104 A
city: HELLERUP
postcode: 2900

contact info
Titolo: Mr.
Nome: Jan
Cognome: Olesen
Email: send email
Telefono: +45 43292835

DK (HELLERUP) participant 302˙340.00
11    PROBIOGEN AG

 Organization address address: Goethestrasse 54
city: Berlin
postcode: 13086

contact info
Titolo: Mrs.
Nome: Andrea
Cognome: Hauptmann
Email: send email
Telefono: +49 30924006148
Fax: +49 3092400619

DE (Berlin) participant 254˙380.00
12 POLYGENE AG CH participant 5˙920.03

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

treatment    therapeutic    autoimmune    plaque    disease    rupture    vaccine    underlying    pathology    clinical    risk    inflammatory    additional    atherosclerosis    immune    cvd    dyslipidemia   

 Obiettivo del progetto (Objective)

'Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underlying pathology of CVD and atherosclerosis is responsible for 70% of all cases of CVD. Extensive studies into the pathology of atherosclerosis show that its etiology is found in a combination of dyslipidemia and a related inflammatory response with an established autoimmune component, while the major cause of acute CVD events, plaque rupture, due to an inflammatory destabilization of the atherosclerotic lesion. CVD is therefore an autoimmune-like disease in the context of a metabolic disease. Thus far, therapeutic approaches in CVD have been focused at normalizing dyslipidemia in order to lower plasma cholesterol. Statins and additional surgical approaches such as angioplasty have achieved a 30% risk reduction for CVD during the last 10-15 years. However, additional approaches to improve the treatment of dyslipidemia by for instance improving the level of the anti-atherogenic lipoprotein HDL have failed in a number of clinical trials. This implicates that new therapeutic approaches are urgently needed to narrow down the remaining 70% risk for CVD. We aim to develop a new immunomodulatory treatment, a therapeutic vaccine that permanently restores the immune balance within the arterial wall by inhibiting the inflammatory responses during atherosclerosis. The VIA consortium aims to develop a vaccine, dissect the immune pathways underlying the beneficial effect of the vaccine, optimize the vaccine, test its safety and perform a phase I clinical trial using the atheroprotective vaccine. The vaccine is foreseen to result in a substantial lowering of the risk for CVD.'

Altri progetti dello stesso programma (FP7-HEALTH)

SURE (2009)

Supporting the Use of Research Evidence (SURE) for Policy in African Health Systems

Read More  

RARE-BESTPRACTICES (2013)

Platform for sharing best practices for management of rare diseases

Read More  

EFACTS (2010)

European Friedreich's Ataxia Consortium for Translational Studies

Read More